by GlyTherix | Jun 5, 2026 | GlyTherix
GlyTherix is pleased to announce the grant of a Canadian patent covering its antibody-drug conjugate (ADC) technology, marking another important milestone in the expansion of the company’s global intellectual property portfolio.The Canadian patent strengthens...
by GlyTherix | Jan 1, 2026 | GlyTherix
GlyTherix will be in San Francisco for JPM Week, engaging with industry leaders, innovators, and the investment community through partnering meetings and 1:1 discussions. Our team will be actively partnering via the QNova JPM Healthcare Conference Partnering Forum and...
by GlyTherix | Oct 27, 2025 | GlyTherix
We’re thrilled to share a great shout-out from Chris Behrenbruch highlighting the thriving radiopharmaceutical ecosystem in Australia at last week’s AusBiotech International Conference 2025. A special congratulations to our very own Gabriel Liberatore, who chaired...
by GlyTherix | Sep 15, 2025 | GlyTherix
Sydney, Australia – 15 September 2025 — GlyTherix, a leading Australian radiopharmaceutical company developing antibody-based therapeutics for the treatment of solid tumors, is proud to announce its participation as an Industry Partner in the Australian Research...
by GlyTherix | May 27, 2025 | GlyTherix
GlyTherix Ltd is proud to announce a strategic supply agreement with Isotopia Molecular Imaging Ltd for the provision of Lutetium-177 (Lu-177) and Terbium-161 (Tb-161), key radioisotopes for advancing our targeted radiopharmaceutical therapies. This collaboration...
by GlyTherix | Jan 13, 2025 | Glypican-1, GlyTherix
On 13 January 2025, GlyTherix Ltd and Eckert & Ziegler announced the expansion of their existing Lutetium-177-based collaboration with a global supply agreement for Actinium-225. Eckert & Ziegler will provide high-quality Ac-225 to support GlyTherix’s clinical...
